FDA Pharmocogenomic Data Guidance To Be Finalized By Year-End
This article was originally published in The Gray Sheet
Executive Summary
FDA will issue a final guidance on pharmacogenomic data submissions later this year, Center for Drug Evaluation & Research Acting Director Steven Galson, MD, told the Biotechnology Industry Organization annual meeting in San Francisco
You may also be interested in...
Drug/Diagnostic Co-Development Guidance Should Be Flexible – Roche Exec
FDA draft guidance on co-development of drug/ diagnostic products likely will be released before 2005, according to the Center for Drug Evaluation & Research's Lawrence Lesko, PhD
Drug/Diagnostic Co-Development Guidance Should Be Flexible – Roche Exec
FDA draft guidance on co-development of drug/ diagnostic products likely will be released before 2005, according to the Center for Drug Evaluation & Research's Lawrence Lesko, PhD
Cancer Segment Likely First Market For Roche’s SynergysDx Program
Roche Diagnostics is anticipating that the drive to commercialize pharmacogenomic technology will create a need for coordinated drug and diagnostic premarket efforts, triggering increased demand for development partnerships between the two sectors